MX361929B - Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. - Google Patents
Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.Info
- Publication number
- MX361929B MX361929B MX2013005532A MX2013005532A MX361929B MX 361929 B MX361929 B MX 361929B MX 2013005532 A MX2013005532 A MX 2013005532A MX 2013005532 A MX2013005532 A MX 2013005532A MX 361929 B MX361929 B MX 361929B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- ccl20
- well
- neutralizing anti
- ccl20 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Abstract
La presente invención se refiere a anticuerpos humanizados, quiméricos y de murino novedosos que tienen especificidad de unión por el ligando de quimiocina CC 20 de humano (CCL20). La presente invención se refiere además a cadenas pesadas y cadenas ligeras de los anticuerpos. La invención también se refiere a ácidos nucleicos aislados, vectores recombinantes y células hospedantes que comprenden una secuencia la cual codifica una cadena pesada y/o una cadena ligera de los anticuerpos y a un método para preparar los anticuerpos. Los anticuerpos anti-CCL20 de la invención se puede utilizar en aplicaciones terapéuticas para tratar, por ejemplo, trastornos inflamatorios y autoinmunes y el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41561410P | 2010-11-19 | 2010-11-19 | |
PCT/US2011/061525 WO2012068540A2 (en) | 2010-11-19 | 2011-11-18 | Neutralizing anti-ccl20 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013005532A MX2013005532A (es) | 2013-09-26 |
MX361929B true MX361929B (es) | 2018-12-19 |
Family
ID=46084688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005532A MX361929B (es) | 2010-11-19 | 2011-11-18 | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. |
Country Status (24)
Country | Link |
---|---|
US (3) | US8491901B2 (es) |
EP (1) | EP2640744A4 (es) |
JP (3) | JP5996549B2 (es) |
KR (1) | KR101919170B1 (es) |
CN (1) | CN103874707B (es) |
AR (1) | AR084141A1 (es) |
AU (2) | AU2011329647B2 (es) |
BR (1) | BR112013012396A2 (es) |
CA (1) | CA2818548A1 (es) |
CL (1) | CL2013001403A1 (es) |
CO (1) | CO6761352A2 (es) |
CR (1) | CR20130228A (es) |
DO (1) | DOP2013000111A (es) |
EA (1) | EA029419B1 (es) |
IL (1) | IL226383B (es) |
MA (1) | MA34738B1 (es) |
MX (1) | MX361929B (es) |
NZ (1) | NZ611269A (es) |
PE (2) | PE20140633A1 (es) |
SG (2) | SG10201509499RA (es) |
TW (1) | TWI589587B (es) |
UA (1) | UA114077C2 (es) |
WO (1) | WO2012068540A2 (es) |
ZA (3) | ZA201303571B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013012396A2 (pt) * | 2010-11-19 | 2020-11-10 | Toshio Imai | anticorpos anti-ccl20 de neutralização |
SG11201404354UA (en) | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
US20150368329A1 (en) * | 2012-10-15 | 2015-12-24 | Oncomed Pharmaceuticals, Inc. | Methods of Treating Ocular Diseases |
CA3208721A1 (en) * | 2014-04-08 | 2015-10-15 | Boston Pharmaceuticals Inc. | Binding molecules specific for il-21 and uses thereof |
CN106413751A (zh) | 2014-05-21 | 2017-02-15 | 辉瑞大药厂 | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 |
MA41480A (fr) * | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | Anticorps qui se lient au ccr6 et leurs utilisations |
EP3233112A2 (en) * | 2014-12-17 | 2017-10-25 | Cancer Research Technology Limited | Anti-cxcl12 antibody molecules and their uses |
CA2988086C (en) | 2015-06-03 | 2023-09-19 | The Medical College Of Wisconsin, Inc. | An engineered ccl20 locked dimer polypeptide |
US11571462B2 (en) | 2015-06-03 | 2023-02-07 | The Medical College Of Wisconsin, Inc. | Engineered CCL20 locked dimer polypeptide |
CN107847764B (zh) * | 2015-07-14 | 2022-07-05 | 免疫医疗有限责任公司 | 用于治疗癌症的组合物和方法 |
WO2017064564A2 (en) * | 2015-10-16 | 2017-04-20 | Glaxosmithkline Intellectual Property Limited | Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody |
BR112018014908A2 (pt) * | 2016-01-21 | 2018-12-18 | The Scripps Research Institute | vacina de opioide sintético |
AU2017209083A1 (en) | 2016-01-22 | 2018-07-12 | Adimab, Llc | Anti-coagulation factor XI antibodies |
GEP20227382B (en) | 2016-06-14 | 2022-05-25 | Merck Sharp & Dohme | Anti-coagulation factor xi antibodies |
CA3043691C (en) * | 2016-11-14 | 2022-11-29 | Dinona | Antibody binding specifically to cd66c and use thereof |
FR3072779A1 (fr) * | 2017-10-19 | 2019-04-26 | Sinnovial | Procede d'estimation de l'efficacite d'un modulateur de la costimulation des lymphocytes t contre la polyarthrite rhumatoide apres reponse inadequate a une biotherapie |
WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
CN111587123A (zh) * | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物 |
WO2020185952A1 (en) * | 2019-03-11 | 2020-09-17 | xCella Biosciences, Inc. | Cd27-binding antibodies and uses thereof |
US11827709B2 (en) * | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
CN113087795A (zh) * | 2019-12-23 | 2021-07-09 | 上海普铭生物科技有限公司 | 针对趋化因子cx3cl1的抗体及其应用 |
KR20240049361A (ko) * | 2021-08-25 | 2024-04-16 | 아이바이오, 인크. | 항-cd25 항체 |
CN116217724B (zh) * | 2021-12-02 | 2023-10-27 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4897348A (en) | 1983-08-25 | 1990-01-30 | Sri International | Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
AU634508B2 (en) | 1988-12-08 | 1993-02-25 | Sandoz Ag | Neutrophil-activating peptide-2 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5179078A (en) | 1989-05-12 | 1993-01-12 | Dana Farber Cancer Institute | Method of suppressing tumor formation in vivo |
US5212073A (en) | 1989-05-12 | 1993-05-18 | Genetics Institute, Inc. | Process for producing human JE cytokine |
DK0494268T4 (da) | 1989-09-25 | 1999-11-08 | Genetics Inst | Fremgangsmåde til inhibering af stamcellers vækst |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
NZ237202A (en) | 1990-02-23 | 1994-01-26 | Bristol Myers Squibb Co | Composition containing beta-lactam antibiotic and cationic oligopeptide |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
WO1992005198A1 (en) | 1990-09-14 | 1992-04-02 | Chiron Corporation | EXPRESSION OF MACROPHAGE INDUCIBLE PROTEINS (MIPs) IN YEAST CELLS |
FR2669930A1 (fr) | 1990-11-29 | 1992-06-05 | Sanofi Sa | Proteine presentant une activite de type cytokine, adn recombinant, vecteur d'expression et hotes permettant son obtention. |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
US5401651A (en) | 1991-10-16 | 1995-03-28 | Walz; Alfred | DNA encoding ENA-78, a neutrophil activating factor |
US5306709A (en) | 1991-11-15 | 1994-04-26 | The University Of Pennsylvania | Suppression of megakaryocytopoiesis by macrophage inflammatory proteins |
US5413778A (en) | 1992-10-05 | 1995-05-09 | The Regents Of The University Of Michigan | Labelled monocyte chemoattractant protein material and medical uses thereof |
US5346686A (en) | 1992-10-05 | 1994-09-13 | Mallinckrodt Medical, Inc. | Labelled interleukin-8 and medical uses thereof |
DK0804070T3 (da) | 1993-03-09 | 2000-08-07 | Genzyme Corp | Fremgangsmåde til isolering af proteiner fra mælk |
US5474983A (en) | 1993-03-15 | 1995-12-12 | The Research Foundation Of State University Of New York | Method of inhibiting pro-inflammatory mediator release from basophils and mast cells |
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
JPH0789866A (ja) | 1993-09-21 | 1995-04-04 | Nippon Kayaku Co Ltd | 感染防御剤 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
CN1143894A (zh) | 1993-12-22 | 1997-02-26 | 人类基因组科学公司 | 巨噬细胞炎性蛋白-3,-4和-1r |
PT767796E (pt) | 1994-05-16 | 2002-03-28 | Human Genome Sciences Inc | Proteina quimiotactica |
JPH10500301A (ja) | 1994-05-16 | 1998-01-13 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | マクロファージ遊走阻止因子−3 |
NZ288799A (en) | 1994-08-23 | 1999-06-29 | Human Genome Sciences Inc | Human chemokine beta-9 polypeptides, polynucleotides encoding the chemokine and preparation thereof |
US5981230A (en) | 1994-08-23 | 1999-11-09 | Human Genome Sciences, Inc. | Polynucleotide encoding chemokine β-4 |
DK0777494T3 (da) | 1994-08-23 | 2004-07-26 | Human Genome Sciences Inc | Humane kemokin-polypeptider |
US6174995B1 (en) | 1994-08-23 | 2001-01-16 | Haodong Li | Human chemokines, CKβ4 and CKβ10/MCP-4 |
JPH10508742A (ja) | 1994-08-23 | 1998-09-02 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒトケモカインポリペプチド |
US6458349B1 (en) | 1995-06-02 | 2002-10-01 | Human Genome Sciences, Inc. | Chemokine β-4 polypeptides |
EP0777494B1 (en) | 1994-08-23 | 2004-03-24 | Human Genome Sciences, Inc. | Human chemokine polypeptides |
AU3681795A (en) | 1994-09-23 | 1996-04-09 | University Of Nebraska Board Of Regents | Polypeptide agonists and antagonists of human interleukin-8 |
KR100507431B1 (ko) | 1994-11-07 | 2005-12-21 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 종양괴사인자-γ |
US5602008A (en) | 1994-11-29 | 1997-02-11 | Incyte Pharmaceuticals, Inc. | DNA encoding a liver expressed chemokine |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
JPH11507205A (ja) | 1995-04-27 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体 |
AU723891B2 (en) | 1995-06-05 | 2000-09-07 | Human Genome Sciences, Inc. | Human chemokine beta-11 and human chemokine alpha-1 |
DK0832233T3 (da) | 1995-06-06 | 2005-01-24 | Smithkline Beecham Corp | Humant kemokin beta-13 |
AU2698795A (en) | 1995-06-06 | 1996-12-24 | Human Genome Sciences, Inc. | Human chemokine beta-12 |
ZA968896B (en) | 1995-10-24 | 1997-04-24 | Smithkline Beecham Corp | Method of mobilizing hematopoietic stem cells |
CA2235360A1 (en) | 1995-10-24 | 1997-05-01 | Smithkline Beecham Corporation | Novel chemokine for mobilizing stem cells |
EP0885293B1 (en) | 1996-02-23 | 2006-06-07 | Human Genome Sciences, Inc. | Human chemokine polypeptides |
WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2250576A1 (en) | 1996-03-27 | 1997-10-02 | Icos Corporation | Monocyte chemotactic protein-5 materials and methods |
US6290948B1 (en) | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
AU3574997A (en) | 1996-07-05 | 1998-02-02 | Schering Corporation | Mammalian chemokine reagents |
DE69738749D1 (de) | 1996-08-16 | 2008-07-17 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
CA2264200A1 (en) | 1996-08-16 | 1998-02-26 | Human Genome Sciences, Inc. | Human endokine alpha |
GB9617923D0 (en) | 1996-08-28 | 1996-10-09 | Smithkline Beecham Plc | Novel receptor |
AU4243097A (en) | 1996-09-10 | 1998-04-02 | Schering Corporation | Mammalian chemokines, related reagents |
WO1998014573A1 (en) | 1996-09-30 | 1998-04-09 | The General Hospital Corporation | Mcp-4 and mcp-5: novel chemokines |
WO1998017800A1 (fr) | 1996-10-17 | 1998-04-30 | Shionogi & Co., Ltd. | Larc, nouvelle chimiokine cc humaine |
KR20050004269A (ko) | 1996-10-25 | 2005-01-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 뉴트로킨 알파 |
AU5255398A (en) | 1996-11-15 | 1998-06-03 | Advanced Research And Technology Institute, Inc. | Exodus chemokine materials and methods |
US7101987B2 (en) * | 1996-11-27 | 2006-09-05 | Schering Corporation | CCL27 polypeptides |
KR20000070174A (ko) | 1997-01-14 | 2000-11-25 | 벤슨 로버트 에이치. | 종양 괴사 인자 수용체 6α 및 6β |
JP2001505060A (ja) | 1997-01-14 | 2001-04-17 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | 腫瘍壊死因子受容体 5 |
US6342363B1 (en) | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
WO1998041629A2 (en) | 1997-03-17 | 1998-09-24 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
US6972323B1 (en) * | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
EP0979282A1 (en) | 1997-04-30 | 2000-02-16 | F. Hoffmann-La Roche Ag | Rat st38.2 chemokine |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
WO1998054202A1 (en) | 1997-05-30 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr10 |
JP2002503963A (ja) | 1997-06-11 | 2002-02-05 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体tr9 |
DE69933998T2 (de) | 1998-03-18 | 2007-10-04 | Corixa Corp., Seattle | Verbindungen und verfahren für therapie und diagnose von lungenkrebs |
AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
US6645491B1 (en) | 1999-02-03 | 2003-11-11 | Schering Corporation | Method for treating inflammatory conditions using an antibody to MIP-3α |
WO2000046248A1 (en) * | 1999-02-03 | 2000-08-10 | Schering Corporation | Use of agonists or antagonists of mip-3a in therapy |
MXPA02008472A (es) | 2000-03-03 | 2004-03-26 | Cambridge Antibody Tech | Anticuerpos humanos contra la eotaxina y su uso. |
US20040197329A1 (en) | 2000-10-13 | 2004-10-07 | Yasunori Nakayama | Remedies or preventives for rheumatoid arthritis |
CA2436671C (en) * | 2000-12-05 | 2015-02-03 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
DE60216606T2 (de) | 2001-06-07 | 2007-04-05 | Chemocentryx Inc., Mountain View | Zellwanderungsassay |
US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
CA2484121A1 (en) | 2002-05-01 | 2003-11-13 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
CA2514117A1 (en) | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
WO2005017149A1 (en) | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
DK1694706T3 (da) | 2003-11-01 | 2012-07-16 | Merck Patent Gmbh | Modificeret anti-CD52-antistof |
NZ554725A (en) * | 2004-10-25 | 2009-10-30 | Merck & Co Inc | Anti-ADDL antibodies and uses thereof |
CA2597098C (en) | 2005-02-08 | 2016-08-02 | Steven R. Ledbetter | Antibodies to tgfbeta |
JP2009096716A (ja) * | 2006-01-19 | 2009-05-07 | Eisai R & D Management Co Ltd | 抗ccl20抗体による自己免疫疾患の治療 |
WO2009062050A2 (en) * | 2007-11-08 | 2009-05-14 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
EP2769993A1 (en) * | 2007-12-14 | 2014-08-27 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
EP2296705A1 (en) * | 2008-06-24 | 2011-03-23 | Hadasit Medical Research Services And Development Ltd. | Ccl20-specific antibodies for cancer therapy |
DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
BR112013012396A2 (pt) * | 2010-11-19 | 2020-11-10 | Toshio Imai | anticorpos anti-ccl20 de neutralização |
WO2013005649A1 (ja) * | 2011-07-01 | 2013-01-10 | 協和発酵キリン株式会社 | 抗ヒトccr6抗体 |
JP7089866B2 (ja) | 2017-12-22 | 2022-06-23 | セーレン株式会社 | 開口部を有するシート状物およびその製造方法 |
-
2011
- 2011-11-18 BR BR112013012396-6A patent/BR112013012396A2/pt not_active Application Discontinuation
- 2011-11-18 UA UAA201307767A patent/UA114077C2/uk unknown
- 2011-11-18 JP JP2013540086A patent/JP5996549B2/ja active Active
- 2011-11-18 MX MX2013005532A patent/MX361929B/es active IP Right Grant
- 2011-11-18 AU AU2011329647A patent/AU2011329647B2/en not_active Ceased
- 2011-11-18 PE PE2013001216A patent/PE20140633A1/es active IP Right Grant
- 2011-11-18 NZ NZ61126911A patent/NZ611269A/en not_active IP Right Cessation
- 2011-11-18 CA CA 2818548 patent/CA2818548A1/en not_active Abandoned
- 2011-11-18 EA EA201390738A patent/EA029419B1/ru not_active IP Right Cessation
- 2011-11-18 SG SG10201509499RA patent/SG10201509499RA/en unknown
- 2011-11-18 PE PE2017002493A patent/PE20180249A1/es unknown
- 2011-11-18 US US13/300,352 patent/US8491901B2/en active Active
- 2011-11-18 KR KR1020137015726A patent/KR101919170B1/ko active IP Right Grant
- 2011-11-18 WO PCT/US2011/061525 patent/WO2012068540A2/en active Application Filing
- 2011-11-18 SG SG2013038245A patent/SG191716A1/en unknown
- 2011-11-18 TW TW100142487A patent/TWI589587B/zh not_active IP Right Cessation
- 2011-11-18 CN CN201180063873.1A patent/CN103874707B/zh not_active Expired - Fee Related
- 2011-11-18 AR ARP110104320 patent/AR084141A1/es not_active Application Discontinuation
- 2011-11-18 EP EP11841462.2A patent/EP2640744A4/en not_active Withdrawn
-
2013
- 2013-05-16 IL IL226383A patent/IL226383B/en active IP Right Grant
- 2013-05-16 ZA ZA2013/03571A patent/ZA201303571B/en unknown
- 2013-05-17 CR CR20130228A patent/CR20130228A/es unknown
- 2013-05-17 DO DO2013000111A patent/DOP2013000111A/es unknown
- 2013-05-17 CL CL2013001403A patent/CL2013001403A1/es unknown
- 2013-06-14 MA MA36013A patent/MA34738B1/fr unknown
- 2013-06-19 CO CO13145744A patent/CO6761352A2/es unknown
- 2013-06-21 US US13/924,433 patent/US9133273B2/en active Active
-
2014
- 2014-08-15 ZA ZA2014/06017A patent/ZA201406017B/en unknown
-
2015
- 2015-08-03 US US14/816,989 patent/US9809647B2/en active Active
-
2016
- 2016-01-21 AU AU2016200359A patent/AU2016200359B2/en not_active Ceased
- 2016-02-10 JP JP2016023617A patent/JP6289520B2/ja active Active
-
2017
- 2017-02-10 ZA ZA2017/01051A patent/ZA201701051B/en unknown
- 2017-12-26 JP JP2017249641A patent/JP2018042578A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX361929B (es) | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
PH12018501473A1 (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
MX2020007021A (es) | Receptor quimerico de antigeno anti-cd19 humanizado. | |
MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
RU2014108208A (ru) | Мыши с гуманизированной универсальной легкой цепью | |
WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
EA034770B8 (ru) | Человеческие антитела к pd-1 | |
EP3593812A3 (en) | Treatment of cancer using chimeric antigen receptor | |
MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
WO2013173496A3 (en) | Cd33 antibodies and use of same to treat cancer | |
NZ586053A (en) | Anti-vegf antibody compositions and methods | |
EA201291161A2 (ru) | Связывающие csf1r антитела | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
UA96141C2 (ru) | Нейтрализующее антитело, которое имеет специфичность к человеческому il-6 | |
NZ599737A (en) | Il-17a antagonists | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
WO2012018767A3 (en) | Antibodies directed against il-17 | |
PH12017500309A1 (en) | Anti-vasa antibodies, and methods of production and use thereof | |
RU2013155843A (ru) | Гуманизированное моноклональное антитело, специфичное к легумаину |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: EISAI R&D MANAGEMENT CO., LTD.* |
|
FG | Grant or registration |